SP-624 is a sirtuin-6 (SIRT6) activator which is under development for the treatment of major depressive disorder and schizophrenia.[1][2][3][4] It is taken by mouth.[1] As of August 2024, SP-624 is in phase 2 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia.[1][2][3] It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.[1][2][4] The drug is said to be a small molecule, but its chemical structure does not yet seem to have been disclosed.[1][2]
| Clinical data | |
|---|---|
| Other names | SP624 |
| Routes of administration | Oral[1] |
| Drug class | Sirtuin-6 (SIRT6) activator[1] |
References
edit- ^ a b c d e f g "SP 624". AdisInsight. 29 August 2024. Retrieved 23 October 2024.
- ^ a b c d "Delving into the Latest Updates on SP-624 with Synapse". Synapse. 21 September 2024. Retrieved 23 October 2024.
- ^ a b Liu R, Li Y, Zheng Q, Ding M, Zhou H, Li X (March 2024). "Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead". Acta Pharm Sin B. 14 (3): 1009–1029. doi:10.1016/j.apsb.2023.10.023. PMC 10935124. PMID 38486982.
- ^ a b "Depression treatment shows 'robust efficacy' in women in phase 2 trial". Daily Medical News, Free CME and Clinical Guidance. 19 October 2022. Retrieved 23 October 2024.
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |